Diseases of the Central nervous system of various origins, especially those associated with vascular diseases and disorders of metabolic processes in the brain, which are accompanied by a deterioration of intellectual and mnestic functions, a decrease in motor activity. Neurotic States that are manifested by lethargy, increased exhaustion, decreased psychomotor activity, impaired attention, memory impairment, and decreased assimilation of information. Mild to moderate depression. Psychoorganic syndromes that manifest themselves as intellectual-mnestic disorders and apathetic-abulic phenomena, as well as sluggish-apathetic States in schizophrenia.
Out of stock
active substance: phenylpiracetam;
1 tablet contains phenylpiracetam 100 mg;
Entrop excipients: potato starch; lactose monohydrate, povidone, sodium starch (type A), calcium stearate.
Entrop Dosage form
Basic physical and chemical properties: flat-cylindrical tablets with a beveled color from white to white with a cream shade.
Psychostimulants and nootropics. ATX code N06B X.
Entrop® has a direct activating effect on the integrative activity of the brain, promotes the consolidation of memory, improves concentration and mental activity, facilitates the learning process, increases the resistance of brain tissue to hypoxia and toxic effects, exhibits an anticonvulsant effect and anxiolytic activity, regulates the processes of activation and inhibition of the central nervous system, improves mood.
The drug has a positive effect on metabolic processes and blood circulation in the brain, stimulates redox processes, increases the energy potential of the body due to the utilization of glucose, improves regional blood flow in ischemic areas of the brain. Increases the content of norepinephrine, dopamine and serotonin in the brain, does not affect the level of gamma-aminobutyric acid (GABA), does not bind to either GABA or GABAB receptors, does not significantly affect the spontaneous bioelectric activity of the brain.
Entrop® does not affect the respiratory and cardiovascular system, exhibits a mild diuretic effect, and has anorexigenic activity when used as a course.
The stimulating effect of Entrop® is in its ability to reveal a moderately pronounced effect in relation to motor reactions, in increasing physical performance, in a pronounced antagonism of the cataleptic action of neuroleptics, as well as in weakening the severity of the hypnotic effect of ethanol and hexenal.
The psychostimulating effect of Entrop® prevails in the ideational sphere. The moderate psychostimulant effect of the drug is combined with anxiolytic activity, improves mood, exhibits some analgesic effect, increasing the threshold of pain sensitivity.
The adaptogenic effect of the drug is manifested in an increase in the body’s resistance to stress under conditions of excessive mental and physical stress, with increased fatigue, hypokinesia and immobilization, at low temperatures.
When taking Entrop®, an improvement in vision was noted, which manifests itself in an increase in acuity and visual fields.
Entrop® improves blood circulation in the lower extremities.
Entrop® stimulates the production of antibodies in response to the introduction of an antigen, which indicates its immunostimulating properties, but at the same time it does not contribute to the development of immediate hypersensitivity and does not change the allergic inflammatory reaction of the skin caused by the introduction of a foreign protein.
With the course application of Entrop®, drug dependence, tolerance, withdrawal syndrome do not develop.
The effect of the drug manifests itself after a single dose is important when using the drug in extreme conditions.
The drug does not possess teratogenic, mutagenic, carcinogenic and embryotoxic properties. Toxicity is low, the lethal dose in an acute experiment is 800 mg / kg.
The drug is rapidly absorbed, penetrates into various organs and tissues, easily passes through the blood-brain barrier. The oral bioavailability of the drug is 100%. The maximum concentration in the blood is reached after 1 hour, the half-life is 3-5 hours. The drug is not metabolized in the body and is excreted unchanged from the body. Approximately 40% is excreted in the urine and 60% in the bile and sweat.
Diseases of the central nervous system of various origins, especially those associated with vascular diseases and metabolic disorders in the brain, which are accompanied by a deterioration in intellectual and mnestic functions, a decrease in motor activity.
Neurotic conditions, manifested by lethargy, increased exhaustion, decreased psychomotor activity, impaired attention, memory impairment, decreased assimilation of information.
Mild to moderate depression.
Psychoorganic syndromes, manifested by intellectual-mnestic disorders and apathic-abulic phenomena, as well as sluggish states in schizophrenia.
Prevention of hypoxia, increasing resistance to stress, correction of the functional state of the body in extreme conditions of professional activity in order to prevent the development of fatigue and increase mental and physical performance, correction of the daily biorhythm, inversion of the sleep-wake cycle.
Chronic alcoholism (in order to reduce the phenomena of asthenia, depression, intellectual-mnestic disorders).
Hypersensitivity to the components of the drug.